

December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2008-008748-26/ Novartis Protocol ID CQAB149B2312

*A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 µg o.d.) on exercise endurance in patients with moderate to severe chronic obstructive pulmonary disease Novartis Pharmaceuticals (COPD)*

Trial CQAB149B2312 was cancelled with no patient enrollment and as such, no results will be reported.